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Creutzfeldt–Jacob disease (CJD) is a rapidly progressive
neurodegenerative disorder characterised by the confor-
mational change of prion protein into an abnormal form
which then self-propagates and deposits in the brain.
Diagnosis is currently based on a combination of the
clinical picture, MRI and EEG findings together with the
detection of protein 14-3-3 in CSF. However, many of the
traditional diagnostic features are non-specific and only
manifest later in the disease course. As a result, an early
confident diagnosis of CJD is often problematic, which
may in turn disadvantage any time-dependent potential
therapies.
This month, we discuss three papers which assess new
approaches to the diagnosis and treatment of CJD. The first
paper publishes the results of an international study
examining the reliability of real-time quaking-induced
conversion (RT-QuIC) as a diagnostic test for CJD. The
second paper is a cross-sectional study assessing the ability
of an assay to diagnose sporadic CJD by the detection of
abnormal prion protein in patient urine. The third paper is a
double-blinded randomised phase II and observational
study looking at the therapeutic effect of Doxycycline in
sporadic CJD.
Cerebrospinal fluid real-time quaking-induced
conversion is a robust and reliable test for sporadic
Creutzfeldt–Jacob disease: an international study
RT-QuIC has previously been shown to be a sensitive and
specific diagnostic test for sporadic CJD. This technique
uses a recombinant prion protein as a substrate, which
aggregates once disease-causing prion protein is added.
This study set out to confirm the reliability of RT-QuIC as
a diagnostic test by demonstrating its reproducibility across
different international centres using a range of recombinant
prion protein substrates and instrumentation.
The study comprised two international ring trials. The
initial ring comprised seven European participants; the
second ring comprised 11 laboratories to include partici-
pants from Australia, Canada and Japan. CSF was provided
by the National CJD Unit, United Kingdom and identical
samples were analysed blind by each of the participating
laboratories. Each laboratory used a standard buffer solu-
tion, however, a range of instrumentation, analytical con-
ditions and types of recombinant prion protein were used.
In the first ring trial, seven European laboratories
received ten identical CSF samples from ten patients. Five
samples were from patients who had confirmed or probable
sCJD with disease duration of between 2 and 12 months
and five samples came from patients with other neurolog-
ical pathology. Six of seven laboratories obtained positive
RT-QuIC responses from all five CJD cases, one laboratory
obtained positive RT-QuIC responses from only four of the
five CJD cases. None of the laboratories obtained positive
RT-QuIC results in any of the five samples from patients
with alternative neurological pathology. In the second ring
trial, 15 CSF samples were sent to 11 centres. Eight
patients had confirmed or probable CJD with disease
duration of between 1 and 26 months. The remaining seven
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had other neurological pathology. All 11 laboratories cor-
rectly identified the eight CSF samples from CJD patients
and none detected a positive RT-QuIC result in CSF from
patients without CJD. The study concludes that an overall
sensitivity of between 85.7 and 100% and specificity of
100% was achieved in the utility of RT-QuIC in detecting
sporadic CJD.
Comment. Although the numbers of patients in both
trials are small, the sensitivity and specificity values
demonstrate the reproducibility of this technique across
international laboratories despite the use of different
recombinant protein, instrumentation and analytic condi-
tions. The wide variation in the age range and duration of
disease of the patients with CJD in both ring trials implies
that this technique is capable of picking up sporadic CJD in
early as well as later stages. It should be noted that only
sporadic CJD patients are included in this study; no
information is provided on the utility of RT-QuIC in
diagnosing variant, inherited or iatrogenic CJD.
McGuire et al (2016) Ann Neurol 80:160–165
Diagnosing sporadic Creutzfeldt–Jacob disease
by the detection of abnormal prion protein
in patient urine
Non-invasive detection of the abnormal prion protein
would clearly be a significant advance in the management
of CJD. Previous assays have detected abnormal protein in
blood and urine of variant but not sporadic CJD. This
cross-sectional, retrospective study assesses the ability of
an assay, developed from a blood test for vCJD, to detect
abnormal protein in the urine of patients with sporadic
CJD. The assay captures disease-associated PrP on a
stainless steel matrix detected using anti-PrP monoclonal
antibodies.
A total of 162 samples were analysed: 91 healthy control
individuals, 34 patients with non-prion degenerative dis-
eases and 37 patients with prion disease (20 of whom had
sporadic CJD). Each sample was tested using triplicate
wells with a quality control panel on each plate and tested
across two independent runs. An arbitrary cut off was
determined from the mean plus five SDs of the panel of five
normal samples in the quality control panel. Only samples
that were reactive in both test runs were scored as positive.
In 55 samples conductivity of the urine samples was also
measured; no correlation was identified between urine
concentration and direct detection assay signals, indicating
patient hydration was not responsible for elevated PrP
signals.
Of the 162 blinded samples, ten samples scored positive
across both runs. All ten positive samples were from
patients with prion disease, of which eight were from
patients with sporadic CJD. No clear correlation was found
with aspects of clinical history, disease progression or
investigation results. The authors concluded that the assay
detected 27% of CJD and 40% of sCJD samples.
Comment. This is the first study to demonstrate detection
of abnormal prion protein in urine in sCJD. Although the
sensitivities demonstrated are low, the authors point out
that the high mean signal obtained for sCJD samples sug-
gests that the sensitivity could be improved considerably
by pre-treatment of urine samples. This study uses good
numbers of patients and sound methodology involving
triplicate analysis of urine samples as well as two inde-
pendent runs. However, there may be difficulties in stan-
dardising and reproducing methodology in different
laboratories.
Luk C et al (2016) JAMA Neurol 72(12):1454–1460
Doxycycline in early CJD: a double-blinded
randomised phase II and observational study
A number of drugs have been tried and failed in clinical
trials of CJD. Doxycycline has been reported to act as an
anti-prion agent in both in vitro and animal models of CJD,
however, a recent phase II trial failed to demonstrate effi-
cacy. It has subsequently been postulated that this may
have been the result of inclusion of patients mainly in
advanced stage of disease. Authors of this study therefore
aimed to explore this further by exploring the therapeutic
efficiency of Doxycycline in the early stages of CJD.
Two groups of patients were enrolled. The first group
was recruited from the National Reference Centre of TSE
surveillance in Germany. Patients with probable or definite
CJD were classified according to established disease cri-
teria. Date of disease onset was determined by interview
with relatives and only patients with a disease duration of
less than 24 months were included. Additional inclusion
criteria were: MMSE [6 and absence of known PRNP
mutations. Seven patients were randomly assigned to the
treatment arm with Doxycycline 100 mg daily and five to
the placebo arm. Disease progression was evaluated by
standardised questionnaire. The second group comprised
patients treated compassionately with Doxycycline. At the
time of diagnosis patients with sCJD were seen by a
physician and assessed with special emphasis on CJD
specific symptoms and MMSE. Treatment with Doxycy-
cline (100 mg daily) was initiated and patients followed up
per protocol. Seventy-seven patients were included
although 22 excluded as a result of an unknown baseline
MMSE, leaving 55 patients for analysis. A matched,
treatment-naive control group of 33 patients with con-
firmed or probable sCJD was identified from historical
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data. The primary outcome measure was survival time,
with quality of life as a secondary outcome measure.
In the randomised, double-blinded placebo controlled
trial, no statistically significant prolongation of survival
time or improvement in quality of life was observed.
However, in the observational study, survival time was
increased compared to controls which the authors postulate
may be a genotype-specific effect since the results sug-
gested this was most apparent in patients MM homozygous
at codon 129. The results of both studies were formally
combined in a meta-analysis demonstrating statistically
significant superiority (p = 0.049) of Doxycycline treat-
ment over control.
Comment. The double-blinded randomised controlled
trial has small numbers which may be a reflection of the
fact that patients and their families do not wish to be ran-
domised to placebo versus a potentially life-prolonging
treatment. Furthermore, the groups in the randomised
control trial appear poorly matched—with the median age
in the control group being 72 years and the Doxycycline
group being 58 years. Furthermore, analysis of survival
from onset, whilst clearly of value, is likely to be difficult
to quantify accurately as the result of recall bias and other
factors. In addition, variation between individual progres-
sion from onset of disease to diagnosis will ultimately
culminate in lead time bias, which is difficult to account
for. The observational study had larger patient numbers but
it remains unclear how study methodology was adapted to
ensure the patients were enrolled at an earlier stage of
disease. Finally, the duration of treatment with Doxycy-
cline was not made clear. The authors also noted that the
cohort demonstrates an atypical distribution of codon 129
genotypes which they concede may be a result of their
selection criteria.
Varges D, Manthey H, Heinemann U et al (2017) J
Neurol Neurosurg Psychiatry 88:119–125
Conclusion
The results of these studies demonstrate some encouraging
progress in the development of new diagnostic and thera-
peutic techniques in Creutzfeldt–Jacob disease. Real-time
induced quaking is already being introduced into labora-
tories as a reliable method of detecting sporadic CJD and
there is hope that less invasive tests for CJD using patient
urine and blood may be on the horizon. However, treatment
of CJD remains problematic and the search for effective
therapeutic agents continues.
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